OHR PHARMACEUTICAL, INC. 20,250,032 Shares of Common Stock And 14,175,059 Warrants to Purchase One Share of Common Stock PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • April 6th, 2017 • Ohr Pharmaceutical Inc • Pharmaceutical preparations • New York
Contract Type FiledApril 6th, 2017 Company Industry JurisdictionOhr Pharmaceutical, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the purchasers (the “Offering”), pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and the Securities Purchase Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”), entered into with the purchasers identified therein (each a “Purchaser” and collectively, the “Purchasers”) an aggregate of 20,250,032 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company and 14,175,059 warrants (the “Warrants”), each Warrant entitles the holder to purchase one share of Common Stock at an exercise price of $1.00 per share at any time prior to the expiration thereof the five year anniversary of issuance (the “Warrant Shares”). The Shares, the Warrants and the Warrant Shares are collectively referred to as the “Securities”. The Purchasers shall receive .7 of a Warrant for each Share purchased an
and Pre-Funded Warrants to Purchase 3,610,997 Shares of Common Stock PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • June 10th, 2015 • Atossa Genetics Inc • Surgical & medical instruments & apparatus • New York
Contract Type FiledJune 10th, 2015 Company Industry JurisdictionAtossa Genetics Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the purchasers, pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and the Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the purchasers identified therein (each a “Purchaser” and collectively, the “Purchasers”), (i) up to an aggregate of 1,829,003 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, and (ii) pre-funded warrants to purchase 3,610,997 shares of Common Stock (the “Pre-funded Warrants”). The Form of the Pre-funded Warrant is attached hereto as Exhibit B. The Shares and the Pre-Funded Warrants to be sold by the Company are collectively referred to as the “Securities. The Company hereby confirms its agreement with Roth Capital Partners, LLC and Dawson James Securities, Inc. (together, the “Placement Agent”) to act as Placement A
GUIDED THERAPEUTICS, INC. Up to 16,785,415 Shares of Common Stock 16,785,415 Warrants to Purchase up to 8,392,708 Shares of Common Stock Up to 8,392,708 Shares of Common Stock Underlying Warrants PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • December 4th, 2014 • Guided Therapeutics Inc • Electromedical & electrotherapeutic apparatus • New York
Contract Type FiledDecember 4th, 2014 Company Industry JurisdictionGuided Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell, pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the purchasers identified therein (each a “Purchaser” and, collectively, the “Purchasers”), (i) to the Purchasers, up to an aggregate of 16,785,415 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, accompanied by a warrant (a “Purchaser Warrant”), in the form attached hereto as Exhibit B, to purchase one-half of a share of Common Stock (a “Purchaser Warrant Share” and, together with the Shares and the Purchaser Warrant Share, the “Securities”), and (ii) to Olympus Securities LLC (the “Placement Agent”), up to four and one-half percent (4.5%) of the total number of Shares and Purchaser Warrants sold to the Purchasers under the Subscrip
GUIDED THERAPEUTICS, INC. Up to 25,178,123 Shares of Common Stock 25,178,123 Warrants to Purchase up to 8,392,708 Shares of Common Stock Up to 8,392,708 Shares of Common Stock Underlying Warrants PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • December 3rd, 2014 • Guided Therapeutics Inc • Electromedical & electrotherapeutic apparatus • New York
Contract Type FiledDecember 3rd, 2014 Company Industry JurisdictionGuided Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell, pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the purchasers identified therein (each a “Purchaser” and, collectively, the “Purchasers”), (i) to the Purchasers, up to an aggregate of 25,178,123 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, accompanied by a warrant (a “Purchaser Warrant”), in the form attached hereto as Exhibit B, to purchase one-half of a share of Common Stock (a “Purchaser Warrant Share” and, together with the Shares and the Purchaser Warrant Share, the “Securities”), and (ii) to Olympus Securities LLC (the “Placement Agent”), up to four and one-half percent (4.5%) of the total number of Shares and Purchaser Warrants sold to the Purchasers under the Subscrip
GUIDED THERAPEUTICS, INC. Up to __________ Shares of Common Stock __________ Warrants to Purchase up to __________ Shares of Common Stock Up to __________ Shares of Common Stock Underlying Warrants PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • November 10th, 2014 • Guided Therapeutics Inc • Electromedical & electrotherapeutic apparatus • New York
Contract Type FiledNovember 10th, 2014 Company Industry JurisdictionGuided Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell, pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the purchasers identified therein (each a “Purchaser” and, collectively, the “Purchasers”), (i) to the Purchasers, up to an aggregate of __________ shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, accompanied by a warrant (a “Purchaser Warrant”), in the form attached hereto as Exhibit B, to purchase one-half of a share of Common Stock (a “Purchaser Warrant Share” and, together with the Shares and the Purchaser Warrant Share, the “Securities”), and (ii) to Olympus Securities LLC (the “Placement Agent”), up to four and one-half percent (4.5%) of the total number of Shares and Purchaser Warrants sold to the Purchasers under the Subscrip
GUIDED THERAPEUTICS, INC. Up to __________ Shares of Common Stock __________ Warrants to Purchase up to __________ Shares of Common Stock Up to __________ Shares of Common Stock Underlying Warrants PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • September 15th, 2014 • Guided Therapeutics Inc • Electromedical & electrotherapeutic apparatus • New York
Contract Type FiledSeptember 15th, 2014 Company Industry JurisdictionGuided Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell, pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the purchasers identified therein (each a “Purchaser” and, collectively, the “Purchasers”), (i) to the Purchasers, up to an aggregate of __________ shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, accompanied by a warrant (a “Purchaser Warrant”), in the form attached hereto as Exhibit B, to purchase one-half of a share of Common Stock (a “Purchaser Warrant Share” and, together with the Shares and the Purchaser Warrant Share, the “Securities”), and (ii) to Olympus Securities LLC (the “Placement Agent”), up to ten percent (10%) of the total number of Shares and Purchaser Warrants sold to the Purchasers under the Subscription Agreements
4,000 Units Each Unit Consisting of One Share of Preferred Stock and A Warrant to Purchase Approximately 636 Shares of Common Stock MINES MANAGEMENT, INC. PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • July 25th, 2014 • Mines Management Inc • Metal mining • New York
Contract Type FiledJuly 25th, 2014 Company Industry JurisdictionMines Management, Inc., an Idaho corporation (the “Company”), proposes, to issue and sell to the purchasers, pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and the Securities Purchase Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the purchasers identified therein (each a “Purchaser” and, collectively, the “Purchasers”), up to an aggregate of 4,000 units (the “Units”), each Unit consisting of (i) one share (the “Shares”) of authorized but unissued preferred stock, no par value per share (the “Preferred Stock”), of the Company, which shares of Preferred Stock shall be convertible into shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) and (ii) a warrant (the “Warrants”) to purchase approximately 636 shares of Common Stock (the “Warrant Shares”). The Units, the Shares, the shares of Common Stock underlying the Preferred Stock (the “Conversion Shares”), th
PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • July 11th, 2014 • Tonix Pharmaceuticals Holding Corp. • Pharmaceutical preparations • New York
Contract Type FiledJuly 11th, 2014 Company Industry JurisdictionTonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), proposes to issue and sell to the purchasers, pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and the Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the purchasers identified therein (each a “Purchaser” and, collectively, the “Purchasers”), up to an aggregate of 657,000 authorized but unissued shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company hereby confirms its agreement with Roth Capital Partners, LLC (the “Placement Agent”) to act as Placement Agent in accordance with the terms and conditions hereof.
DIGITAL CINEMA DESTINATIONS CORP. 1,141,000 shares of Class A Common Stock PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • October 4th, 2013 • Digital Cinema Destinations Corp. • Services-motion picture theaters • New York
Contract Type FiledOctober 4th, 2013 Company Industry JurisdictionDigital Cinema Destinations Corp., a Delaware corporation (the “Company”), proposes to issue and sell to the purchasers, pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and the Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the purchasers identified therein (each a “Purchaser” and, collectively, the “Purchasers”), up to an aggregate of 1,141,000 authorized but unissued shares (the “Shares”) of Class A common stock, par value $0.01 per share (the “Common Stock”), of the Company. The Company hereby confirms its agreement with Barrington Research Associates, Inc. (the “Placement Agent”) to act as Placement Agent in accordance with the terms and conditions hereof.
CATALYST PHARMACEUTICAL PARTNERS, INC. 8,800,000 shares of Common Stock PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • September 5th, 2013 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • California
Contract Type FiledSeptember 5th, 2013 Company Industry JurisdictionCatalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the purchasers, pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and the Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the purchasers identified therein (each a “Purchaser” and, collectively, the “Purchasers”), up to an aggregate of 8,800,000 authorized but unissued shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company hereby confirms its agreement with Roth Capital Partners, LLC (the “Placement Agent”) to act as Placement Agent in accordance with the terms and conditions hereof.
CATALYST PHARMACEUTICAL PARTNERS, INC. 4,000,000 shares of Common Stock and Warrants to purchase up to 1,200,000 shares of Common Stock PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • August 28th, 2012 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 28th, 2012 Company Industry JurisdictionCatalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the purchasers, pursuant to the terms and conditions of this Placement Agent Agreement (this “Agreement”) and the Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the purchasers identified therein (each a “Purchaser” and, collectively, the “Purchasers”), up to an aggregate of (i) 4,000,000 authorized but unissued shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company and (ii) warrants (the “Warrants”) to purchase up to 1,200,000 shares of Common Stock (the “Warrant Shares”). The form of the Warrant is attached hereto as Exhibit B. The Shares, the Warrants and the Warrant Shares are collectively referred to as the “Securities.” The Company hereby confirms its agreement with Roth Capital Partners, LLC (the “Placement Agent”) to act as Placement Agent in accordance wit